Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines
Authors:
- Roger M. MacklisRMRoger M. Macklis
- Urs O. HäfeliUHUrs O. Häfeli
- 1 February 2005
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 61 (2) , 535-542
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- The use of Bisphosphonates in Patients with Breast CancerCancer Control, 2002
- American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple MyelomaJournal of Clinical Oncology, 2002
- Adjuvant bisphosphonate therapy: The futureSeminars in Oncology, 2001
- How are bisphosphonates used today in breast cancer clinical practice?Seminars in Oncology, 2001
- Factors influencing the role of bisphosphonates in breast cancer managementSeminars in Oncology, 2001
- American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast CancerJournal of Clinical Oncology, 2000
- Bisphosphonates in prostate carcinomaCancer, 1997
- Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activityBritish Journal of Haematology, 1997
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996
- Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.Journal of Clinical Investigation, 1991